Of note, the percentage of MAGE-A4-positive patient tumors observed in select cancer subtypes has been reported as follows: 47% in ovarian cancers, 19–35% in lung cancers, 22% in colon cancers and 13% in breast cancers39. Here, MAGEA4 is linked to ovarian carcinoma.